KR20240117104A - 핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도 - Google Patents

핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도 Download PDF

Info

Publication number
KR20240117104A
KR20240117104A KR1020247021150A KR20247021150A KR20240117104A KR 20240117104 A KR20240117104 A KR 20240117104A KR 1020247021150 A KR1020247021150 A KR 1020247021150A KR 20247021150 A KR20247021150 A KR 20247021150A KR 20240117104 A KR20240117104 A KR 20240117104A
Authority
KR
South Korea
Prior art keywords
nucleotide
nucleotide sequence
sirna
identification number
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247021150A
Other languages
English (en)
Korean (ko)
Inventor
지카이 리앙
홍얀 창
샨 가오
슈펭 딩
Original Assignee
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 filed Critical 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드
Publication of KR20240117104A publication Critical patent/KR20240117104A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247021150A 2021-12-21 2022-12-19 핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도 Pending KR20240117104A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111575800 2021-12-21
CN202111575800.2 2021-12-21
PCT/CN2022/139942 WO2023116607A1 (zh) 2021-12-21 2022-12-19 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Publications (1)

Publication Number Publication Date
KR20240117104A true KR20240117104A (ko) 2024-07-31

Family

ID=86901326

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247021150A Pending KR20240117104A (ko) 2021-12-21 2022-12-19 핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도

Country Status (8)

Country Link
US (1) US20250057870A1 (https=)
EP (1) EP4455284A1 (https=)
JP (1) JP2024546667A (https=)
KR (1) KR20240117104A (https=)
CN (1) CN118202049A (https=)
AU (1) AU2022422864A1 (https=)
CA (1) CA3242059A1 (https=)
WO (1) WO2023116607A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
JP7610268B2 (ja) 2019-05-22 2025-01-08 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
WO2020233680A1 (zh) 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
EP3978609A4 (en) 2019-05-24 2024-02-07 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN121780524A (zh) * 2024-08-02 2026-04-03 北京尧景基因技术有限公司 抑制MAPT基因表达的siRNA及其缀合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143371A2 (en) * 2008-05-21 2009-11-26 Intradigm Corporation COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
WO2010064851A2 (ko) * 2008-12-02 2010-06-10 울산대학교 산학협력단 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물
US20120136073A1 (en) 2010-11-15 2012-05-31 Life Technologies Corporation Amine-Containing Transfection Reagents and methods for making and using same
WO2017151732A1 (en) * 2016-03-02 2017-09-08 Beth Israel Deaconess Medical Center Technology Venture Office, Br2 Therapeutic targets for lin-28-expressing cancers
AU2018216509B2 (en) * 2017-01-31 2024-02-29 Curigin Co.,Ltd. Nucleic acid simultaneously inhibiting expression of mTOR gene and STAT3 gene
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
EP3732185B1 (en) 2017-12-29 2025-02-26 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2019217459A1 (en) 2018-05-07 2019-11-14 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
WO2020018461A1 (en) * 2018-07-16 2020-01-23 The University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases
CN112423795A (zh) * 2018-12-28 2021-02-26 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Also Published As

Publication number Publication date
CN118202049A (zh) 2024-06-14
AU2022422864A1 (en) 2024-07-04
CA3242059A1 (en) 2023-06-29
WO2023116607A1 (zh) 2023-06-29
WO2023116607A9 (zh) 2023-10-05
JP2024546667A (ja) 2024-12-26
US20250057870A1 (en) 2025-02-20
EP4455284A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
EP3315608B1 (en) Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof
KR20240117104A (ko) 핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도
CN103747805B (zh) 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型（dm1）的化合物
JP2024528634A (ja) 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物及び複合体並びに調製方法と使用
EP3978609A1 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2006311912A1 (en) Peptide-dicer substrate RNA conjugates as delivery vehicles for siRNA
CN108220293A (zh) 一种小干扰核酸和药物组合物及其用途
CA3020487A1 (en) Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
JP2024525800A (ja) 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
CN120981570A (zh) 靶向agt的多核酸分子及其用途
EP4273245A1 (en) Nucleic acid, pharmaceutical composition and sirna conjugate containing the nucleic acid, preparation method therefor, and use thereof
CN118360282A (zh) 核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN116370491A (zh) 反义寡核苷酸剂在治疗冠状病毒相关疾病中的应用
WO2026046236A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN114632089B (zh) 含酰基糖胺基团化合物在制备治疗新型冠状病毒肺炎药物中的应用及疾病的治疗方法
WO2026057066A1 (zh) 寡核苷酸、寡核苷酸缀合物及组合物和用途
CN119968465A (zh) 一种siRNA、siRNA缀合物、药物组合物及其用途
WO2023116764A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及其用途
EP4678746A1 (en) Pharmaceutical composition and use thereof
WO2025140402A1 (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2023088455A1 (zh) 一种核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
WO2026052021A1 (zh) 寡核苷酸、寡核苷酸缀合物及组合物和用途
WO2026052079A1 (zh) 寡核苷酸、寡核苷酸缀合物及组合物和用途
CN119113136A (zh) RNAi剂在治疗牙周炎及相关疾病中的应用
WO2026017176A1 (zh) 靶向微管相关蛋白Tau基因的寡核苷酸及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000